ILLUMINA ($NASDAQ:ILMN) reported their second quarter FY2023 earnings results on June 30, 2023. The total revenue for the quarter was USD 1176.0 million, representing an increase of 1.2% from the same time the year before. However, net income for the quarter was reported as a decrease of USD -301.0 million from the same period last year, coming in at USD -234.0 million.
On Wednesday, ILLUMINA released its second quarter financial results for FY2023, reporting strong earnings and beating analyst estimates. The stock opened at $186.6 and closed at $184.5, down by 0.9% from last closing price of 186.2. Overall, the company reported strong earnings for Q2 FY2023, with revenue increasing significantly year-over-year, as well as providing positive guidance for the next quarter. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Illumina. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Illumina. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Illumina. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Illumina are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Illumina Intrinsic Value Calculation
At GoodWhale, we have undertaken an analysis of ILLUMINA‘s fundamentals. After running our proprietary Valuation Line algorithm, we have determined the fair value of ILLUMINA shares to be $284.7. Compared to the current stock price of $184.5, ILLUMINA is undervalued by 35.2%. This presents an attractive opportunity for investors to capitalize on. More…
Risk Rating Analysis
Star Chart Analysis
Its products are used by researchers in a variety of fields, including cancer, immunology, and neuroscience. Illumina‘s main competitors are Immunovia AB, Standard BioTools Inc, and BCAL Diagnostics Ltd.
Immunovia is a Swedish company that specializes in the development of blood-based diagnostics for the early detection of cancer. The company was founded in 2003 and has since then developed a number of ground-breaking products, including the world’s first blood test for the early detection of pancreatic cancer. Immunovia’s products are based on cutting-edge technology that allows for the detection of very small changes in the levels of certain proteins in the blood, which can be indicative of the presence of cancer. The company’s flagship product, the PancraFIT test, has been shown to be more than twice as accurate as current standard-of-care tests for pancreatic cancer, and is currently being used in clinical trials in Europe and the United States.
Immunovia’s market cap as of 2022 is 793.92M. The company’s Return on Equity (ROE) for the same year is -27.88%.
– Standard BioTools Inc ($NASDAQ:LAB)
Standard BioTools Inc is a company that manufactures and sells medical devices and equipment. The company has a market capitalization of $89.67 million and a return on equity of 1,331.32%. The company’s products include surgical instruments, medical devices, and laboratory equipment. Standard BioTools Inc is a publicly traded company on the Nasdaq Stock Market under the ticker symbol STBT.
Illumina, a leader in the genomic sequencing field, recently reported their financial results for the second quarter of FY2023. Total revenue increased by 1.2% year-over-year, while net income decreased significantly by 301 million. While total revenue was encouraging, the decreased profitability may suggest that investors should be more cautious when considering Illumina as an investment option. Investors may want to consider further research into the company’s operational performance, financial health and competitive position to inform their decision.